The U.S. FDA has approved Innovent Biologics, Inc.’s IND application to initiate a phase I clinical trial of its oral GLP-1R agonist IBI-3032.

Hemispherian AS has received IND clearance for GLIX-1 for the treatment of glioblastoma from the U.S. FDA. GLIX-1 targets DNA repair mechanisms, specifically the enzyme TET2, selectively in tumor cells while sparing healthy tissues.

Madrigal Pharmaceuticals Inc.’s long-awaited business development pact became reality by way of an exclusive global license agreement that could be worth more than $2 billion with CSPC Pharmaceutical Group Ltd., of Shijiazhuang, China, for SYH-2086. The candidate is a preclinical oral, small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist and orforglipron derivative.

Antibiotics specialist Bioversys AG has sealed a potential CHF529 million (US$667.5 million) deal with Shionogi Co. Ltd., in which they will work together on novel ansamycins for treating multidrug-resistant lung infections caused by non-tuberculous mycobacteria.

Researchers at the Massachusetts Institute of Technology and Recursion Pharmaceuticals Inc. have released an open-source AI model that can predict the binding strength of small molecules as well as structures of proteins and biomolecular complexes. The model, which is called Boltz-2 and was released by the research team on the developer platform Github on June 6, addresses a major bottleneck in drug discovery with its improved ability to predict binding strengths.

At the 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (ADPD), researchers from Beijing Joekai Biotechnology LLC presented the discovery process and preclinical results for 50561.

Researchers from Lund University and collaborators have investigated the potential of selectively targeting TUBG1 as a therapeutic strategy in cancer treatment.